Autres langues Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
14,65 ^USD	+3,31 %		-0,14 %	-9,18 %

13/03	Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
06/02	La perte nette de Deciphera Pharmaceuticals au 4ème trimestre se réduit, le chiffre d'affaires augmente	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)	18/04
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	09/04
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	27/02
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	06/02
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q4 Revenue $48.3M, vs. Street Est of $46.8M	06/02
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results	06/02
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/02
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/02
North American Morning Briefing : Rate Doubts Keep -2-	06/02
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024	01/02
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	18/01
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	18/01
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries	12/01
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe	12/01
GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe	10/01
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	08/01
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company	08/01
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	05/01
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	05/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Deciphera Pharmaceuticals, Inc.

Actions

DCPH

US24344T1016

Autres langues

Filtres